Pompe Disease (Glycogen Storage Disease II)
An inherited disorder caused by acid alpha-glucosidase (GAA) deficiency, leading to glycogen accumulation in muscle and progressive weakness affecting the heart and skeletal muscles.
- Caused by GAA gene mutations
- Acid alpha-glucosidase enzyme deficiency
- Autosomal recessive inheritance
- Enzyme replacement therapy available
- Disease Group
- Lysosomal Storage Disorders / Glycogen Storage Disease
- Inheritance Pattern
- Autosomal Recessive (GAA gene)
- Onset Range
- Infancy (classic) to Adulthood (late-onset)
- Advanced Therapies
- Enzyme Replacement Therapy, Newer Next-Generation ERT Options
Condition Overview
Pompe Disease, also known as Glycogen Storage Disease Type II, is a rare inherited disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA). This enzyme is needed to break down glycogen inside lysosomes; when it is deficient, glycogen accumulates within cells, particularly affecting skeletal muscle, the heart, and the respiratory muscles.
The disease spans a wide clinical spectrum. Infantile-onset Pompe Disease presents in the first months of life with severe hypotonia and a thickened heart muscle (hypertrophic cardiomyopathy), and without treatment is typically rapidly progressive. Late-onset Pompe Disease, presenting from later childhood through adulthood, primarily affects skeletal and respiratory muscles, with the heart usually less involved, and progresses more slowly.
Because Pompe Disease can resemble other neuromuscular conditions, especially in its later-onset form, a high index of suspicion combined with enzyme and genetic testing is important for timely diagnosis, particularly because enzyme replacement therapy is available and most effective when started early.
Types and Clinical Subtypes
Pompe Disease is classified primarily by age of onset and degree of cardiac involvement.
Symptoms and Signs
Symptoms reflect progressive glycogen accumulation in muscle tissue, with the pattern and severity differing between infantile-onset and late-onset disease.
Causes and Risk Factors
Pompe Disease is caused entirely by inherited genetic mutations affecting the GAA enzyme; it is not related to lifestyle or environmental exposures.
Diagnosis and Investigations
Diagnosis combines clinical suspicion, enzyme testing, and genetic confirmation, with newborn screening increasingly available in some regions.
Disease Severity Stratification
Pompe Disease does not use a tumor-style staging system; clinicians classify disease by age of onset and degree of cardiac involvement, which strongly influences urgency and treatment approach.
Standard Treatment Options
Enzyme replacement therapy is the cornerstone of treatment, combined with multidisciplinary supportive care.
Advanced and Emerging Treatment Options
Enzyme replacement therapy has transformed outcomes in Pompe Disease, and newer formulations and complementary approaches continue to expand options.
Enzyme Replacement Therapy
Recombinant human acid alpha-glucosidase (alglucosidase alfa)
The original approved enzyme replacement therapy for Pompe Disease, used across both infantile and late-onset forms.
Next-Generation Enzyme Replacement Therapy
Newer GAA enzyme formulations (e.g., avalglucosidase alfa, cipaglucosidase alfa)
Next-generation enzyme replacement therapies designed for improved cellular uptake and glycogen clearance are approved in several regions.
Gene Therapy
Investigational gene therapy approaches
Early-phase research is exploring gene transfer strategies aimed at providing sustained GAA enzyme production.
Biomarkers and Molecular Testing
Biochemical and genetic markers support diagnosis, phenotype prediction, and monitoring of treatment response.
When a Second Opinion May Be Important
Because Pompe Disease can be mistaken for other neuromuscular conditions, specialist re-evaluation can be valuable at several points in the care journey.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Prognosis in Pompe Disease has improved substantially with the availability of enzyme replacement therapy, particularly when treatment begins early, though outcomes still vary by disease subtype and timing of diagnosis.
Supportive Care and Living with Pompe Disease
Comprehensive supportive care complements enzyme replacement therapy to maintain function and quality of life.
How CancerFax Helps You Explore Treatment Options
CancerFax can help patients and families with Pompe Disease obtain specialist medical report review, coordinate second opinions, and connect with centers experienced in enzyme replacement therapy and comprehensive Pompe Disease care.
Get a free case reviewFrequently Asked Questions
Pompe Disease, also called Glycogen Storage Disease Type II, is a rare inherited disorder caused by deficiency of the enzyme acid alpha-glucosidase, leading to glycogen accumulation in muscle tissue and progressive weakness.
It is caused by mutations in the GAA gene, inherited in an autosomal recessive pattern.
In infants, early signs include severe floppiness (hypotonia) and a thickened heart muscle; in later-onset disease, early signs often include progressive muscle weakness and difficulty climbing stairs.
Diagnosis typically involves an acid alpha-glucosidase enzyme activity test, often via dried blood spot, confirmed with GAA gene sequencing.
Yes, enzyme replacement therapy is approved and can significantly improve muscle and cardiac function, particularly when started early.
Infantile-onset disease presents in the first months of life with severe hypotonia and heart involvement, while late-onset disease presents later in life with progressive skeletal and respiratory muscle weakness, usually without major cardiac involvement.
Care typically involves medical geneticists, neuromuscular specialists, cardiologists, pulmonologists, and physical therapists.
In some countries, Pompe Disease is included in newborn screening programs, which can allow earlier diagnosis and treatment initiation.
Yes. Because Pompe Disease is autosomal recessive, genetic counseling helps families understand recurrence risk and testing options for future pregnancies.
Yes. CancerFax can help patients and families review medical reports, coordinate second opinions with specialists experienced in Pompe Disease, and connect with centers offering enzyme replacement therapy and related research programs, including cross-border coordination where needed.
Get Expert Guidance for Pompe Disease
Connect with specialists experienced in enzyme replacement therapy to review your medical reports and discuss treatment options.